Global AntiIdiopathic Pulmonary Fibrosis Drugs Overview
Idiopathic pulmonary fibrosis is a disease which belongs to a vast group of more than 200 lung diseases. The global anti-idiopathic pulmonary fibrosis drugs market is majorly driven by the increase in geriatric population and prevalence of pulmonary fibrosis across the globe. Boost in the smoker population is also leading to various lung diseases which in turn is propelling the growth of the global market. However, as the etiology of disease is unknown, curing idiopathic pulmonary fibrosis is difficult, which is the major restraining factor for the target market growth. The Anti-idiopathic pulmonary fibrosis drugs market was valued at US$ XX Mn in 2018 and is expected to reach to the value of US$ XX Mn by 2029, expanding at a CAGR of XX over 2019 to 2027.
Global anti-idiopathic pulmonary fibrosis drugs market report published by Prophecy Market Insights offers holistic view of various influencing factors and aims to answer all the target market related questions.
The research scope provides comprehensive market size, and other in-depth market information details such as, market growth supporting factors, restraining factors, trends, opportunities, market risk factors, market competition, product and services advancements and launches, product/services related regulations overview, and recent developments for the mentioned forecast period. In addition, the report provides key examination of market players operating in the specific market and analysis and outcomes related with the target market for more than 20 countries.
In the current research scope 2018 is considered as base year and 2019 is estimated year for market value/volume calculations. The report offers market estimates for the forecast period – 2019 to 2029. The report provides factual inputs and analysis based on primary and secondary research, which includes insights gained through in-depth interviews with primary research participants. Also, the data is gathered from authentic secondary sources and is verified by key opinion leaders in the target market. The in-house research is applied on gathered information to provide more accurate data points and reduce the margin of error. The in-house research and analysis efforts include various tools and 360o data analysis methodology.
The global anti-idiopathic pulmonary fibrosis drugs market report segments the market on the basis of marketed drug, mechanism of action, innovator and off-label drug, and region.
The report expected to answer various target market related questions and offers insights on:
- Definition, description, overview of market growth influencing factors, and forecast for the target market
- Scope for related market in the forecast period
- Analysis and outcome for the global anti-idiopathic pulmonary fibrosis drugs market by segment and region followed by countries
- Market segmentation, dominating segment and region followed by country along with market value, share, Y-o-Y growth, CAGR, forecast, and contribution in the market
- Key market player profiles, their recent developments, strategies, financial details, key competencies, presence by region, and product portfolio
- Valuable insights, data, and forecast that can be referenced to plan business strategies, to tap market opportunities, understand business related risks, derive business goals, to recognize trends, and understand target customers/end users
- Insights on recent technologies, pipeline products, regulations related with target market, market investment, and offers insights on political and economical factors that may influence market growth
- PEST Analysis, PORTER’s five forces analysis, opportunity map analysis, drivers and restraints impact analysis, and market attractiveness index
Key players in the global anti-idiopathic pulmonary fibrosis drugs market include,
- Afferent Pharmaceuticals
- Asahi Kasei Pharma
- Bellerophon Therapeutics
- Boehringer Ingelheim
- FibroGen Inc.
- Galecto Biotech
- Genentech
- Global Blood Therapeutics
- GSK Plc.
- Kadmon Pharmaceuticals
Prophecy Market Insights offers required customization on this report according to specific business requirements.
Global AntiIdiopathic Pulmonary Fibrosis Drugs Table of Contents
Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
Research Typeology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Technologys
- Key Thickness Insights
- Secondary Data
- Major Secondary Technologys
- Secondary Technologys
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
Market Preview
- Executive Summary
- Key Findings—Global Outlook for medical carts Strategies
- Key Questions this Study will Answer
- Market Snippet, By Marketed Drug
- Market Snippet, By Mechanism of Action
- Market Snippet, By Innovator and Off-Label Drugs
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restrains
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Marketed Drug, Forecast Period up to 10 Years, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Esbriet
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Ofev
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Y-o-Y Growth (%), Forecast Period up to 10 Years
Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Mechanism of Action, Forecast Period up to 10 Years, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Antifibrotics
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Tyrosine Kinase Inhibitors
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Chronic Back Pain
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Anti-Inflammatory Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Immunosuppressant’s
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Innovator and Off-Label Drugs, Forecast Period up to 10 Years, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Innovator Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Off-Label Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Region, Forecast Period up to 10 Years, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Marketed Drug, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Mechanism of Action, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Innovator and Off-Label Drugs, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Marketed Drug, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Mechanism of Action, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Innovator and Off-Label Drugs, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Marketed Drug, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Mechanism of Action, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Innovator and Off-Label Drugs, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Marketed Drug, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Mechanism of Action, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Innovator and Off-Label Drugs, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Marketed Drug, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Mechanism of Action, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Innovator and Off-Label Drugs, Forecast Period up to 10 Years
- Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
- GCC
- Israel
- South Africa
- Rest of Middle East
Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
Company Profiles
- Afferent Pharmaceuticals
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Asahi Kasei Pharma
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bellerophon Therapeutics
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Boehringer Ingelheim
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- FibroGen Inc.
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Galecto Biotech
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Genentech
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Global Blood Therapeutics
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- GSK Plc.
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Kadmon Pharmaceuticals
- Company Overview
- Technology Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
The Last Word
- Future Impact
- About Us
- Contact
FAQs
The global anti-idiopathic pulmonary fibrosis drugs market report segments the market on the basis of marketed drug, mechanism of action, innovator and off-label drug, and region.
Emerging trends include the development of targeted therapies, advancements in diagnostic tools, and a growing focus on combination therapies. Opportunities arise from increased awareness, ongoing research, and the potential for innovative treatment approaches.
Key factors include the rising prevalence of idiopathic pulmonary fibrosis (IPF), advancements in understanding the disease's mechanisms, increased research and development in respiratory medicine, and the need for effective and well-tolerated treatment options.
Regions covered include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the market due to a higher prevalence of idiopathic pulmonary fibrosis, advanced healthcare infrastructure, and significant investments in research and development in the region.
Afferent Pharmaceuticals, Asahi Kasei Pharma, Bellerophon Therapeutics, Boehringer Ingelheim, FibroGen Inc., Galecto Biotech, Genentech, Global Blood Therapeutics, GSK Plc., Kadmon Pharmaceuticals,